HOME Top Market Reports Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020

Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020

By: marketsandmarkets.com
Publishing Date: April 2014
Report Code: PH 2438

Discount on Reports  

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and the allogeneic stem cell therapy segment is expected to grow at the highest CAGR of 40% in the forecast period (2015-2020).

Moreover, based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases; CVS diseases, wounds and injuries, and others. Immune system diseases are expected to command the largest share of the global market in 2015. The Central Nervous System (CNS) disease segment will be the fastest-growing segment of the global market in the forecast period.

A number of factors such as increasing funding from various government and private organizations, growing industry focus on stem cell research, and rising global awareness about stem cell therapies through various organizations are driving the growth of the global market. In addition, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cell therapy are other factors that are propelling the growth of the market. However, factors such as lack of required infrastructure, ethical issues related to embryonic stem cell, and difficulties related with the preservation of stem cell are restraining the growth of the market.

Based on geography, the market is divided into North America, Asia-Pacific, Europe, and the Rest of the World (RoW). In 2015, North America is expected to hold the largest share in the global market, followed by Asia-Pacific, Europe, and the RoW (Rest of the World). The Asia-Pacific region is estimated to grow at the highest CAGR in the forecast period, owing to factors such as presence of huge patient population base, increasing regulatory support through favorable government policies, strong product pipelines of stem cell therapies, and rising licensing activities.

Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc.(U.S.) are adopting several growth strategies such as new product approvals, partnerships, agreements, collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends.

Scope of the Report

This research report categorizes the stem cell therapy market into the following segments and sub-segments:

By Mode of Therapy

  • Allogeneic Stem Cell Therapy Market 
    • GIT diseases
    • Eye Diseases
    • Musculoskeletal Disorders
    • Metabolic Diseases
    • CVS Diseases
    • CNS Diseases
    • Immune System Diseases
    • Wounds and Injuries
    • Others
  • Autologous Stem Cell Therapy Market 
    • GIT Diseases
    • Musculoskeletal Disorders
    • CVS Diseases
    • CNS Diseases
    • Wounds and Injuries
    • Others

By Therapeutic Applications

  • GIT Diseases
  • Eye Diseases
  • Musculoskeletal Disorders
  • Metabolic Diseases
  • CVS Diseases
  • CNS Diseases
  • Immune System Diseases
  • Wounds and Injuries
  • Others

By Geography

  • North America
  • Asia-Pacific
  • Europe
  • RoW (Rest of the World)

Customization Options:

With the given market data, MarketsandMarkets offer customizations as per the Company’s specific needs. The following customization options are available for the report –

  • Product Analysis
    • Product Matrix which gives a detailed comparison of product portfolio of each company OR
    • Comprehensive information on applications  of the products (Segment wise)
  • Epidemiology Data
    • Country specific Prevalence for top five diseases that can be treated using stem cell therapy  OR
    • Disease progression (Pattern analysis)
  • Geographic Analysis
    • Further country wise (top 2 countries) market breakdown for the North America, Europe, Asia-Pacific, and Rest of World
  • Company Information
    • Detailed analysis and profiling of additional market players (Upto 5)

Table Of Contents
       
1 Introduction (Slide No. - 24)   
    1.1 Objectives    
    1.2 Markets Covered    
    1.3 Stakeholders    
    1.4 Market Size Estimation    
          1.4.1 Market Definition   
          1.4.2 Market Scope   
    1.5 Research Methodology    
          1.5.1 Secondary Research   
          1.5.2 Primary Research    
          1.5.3 Analysis & Output   
          1.5.4 Assumptions   
          1.5.5 Limitations   
          1.5.6 Key Data Points Taken From Secondary Sources   
          1.5.7 Key Data Points Taken From Primary Sources   
       
2 Executive Summary (Slide No. - 35)      
       
3 Market Dynamics (Slide No. - 41)      
    3.1 Introduction    
    3.2 Drivers    
          3.2.1 Increasing Funding for New Stem Cell Lines   
          3.2.2 Development of Advanced Genomic Methods for Stem Cell Analysis   
          3.2.3 Increasing Focus on Human Embryonic Stem Cells   
          3.2.4 Increasing Approvals of Clinical Trials for Stem Cells Therapy   
    3.3  Restraints    
          3.3.1 Lack of Required Infrastructures   
          3.3.2 Difficulties Related With The Preservation of Stem Cells   
          3.3.3 Ethical Issues Related to Embryonic Stem (ES) Cell   
          3.3.4 Immunorejection After Stem Cell Transplantation   
          3.3.5 Complexity Involved in Identification  of Stem Cells in Adult Tissues   
    3.4 Opportunities    
          3.4.1 Lack of Effective Treatments to Cure Diseases   
          3.4.2 Evolution of New Stem Cell Therapies   
          3.4.3 Emergence of Induced Pluripotent Stem (IPS) Cells As An Alternative to Escs   
          3.4.4 Emerging Markets Unfolds New Avenues Due to Low Regulatory Barriers and Clinical Trial Cost   
    3.5 Challenges    
          3.5.1 Dearth of Reimbursements   
          3.5.2 High Costs Incurred in Stem Cell Processing   
          3.5.3 Need of Automated Cell Culturing    
          3.5.4 Lack of Clear Regulatory Guidelines   
    3.6 Winning Imperatives    
          3.6.1 Partnering With Academic Institutes  
          3.6.2 Collaborating With Giant Pharmaceutical Firms   
          3.6.3 High Focus on Emerging Markets   
    3.7 Burning Issues    
          3.7.1 Establishment of Safety Profiles   
          3.7.2 Granting Orphan Drug Status to Stem Cell Therapeutics   
       
4 Pipeline Analysis (Slide No. - 56)     
       
5 Investor Network (Slide No. - 65)     
       
6 By Mode of Therapy (Slide No. - 70)      
    6.1 Introduction    
    6.2 Allogeneic Stem Cell Therapy Market, By Application    
          6.2.1 Introduction   
          6.2.2 Eye Diseases   
          6.2.3 GIT Diseases   
          6.2.4 Immune System Diseases   
          6.2.5 Metabolic Diseases   
          6.2.6 Musculoskeletal Disorders   
          6.2.7 CNS Diseases   
          6.2.8 CVS Diseases   
          6.2.9 Wounds and Injuries   
          6.2.10 Other Diseases   
    6.3 Autologous Stem Cell Therapy Market, By Application    
          6.3.1 Introduction   
          6.3.2 GIT Diseases   
          6.3.3 CNS Diseases   
          6.3.4 Musculoskeletal Disorders   
          6.3.5 Wounds and Injuries   
          6.3.6 CVS Diseases   
          6.3.7 Other Diseases   
       
7  By Therapeutic Applications (Slide No. - 94)      
    7.1 Introduction    
    7.2 Eye Diseases     
    7.3 GIT Diseases    
    7.4 Immune System Diseases    
    7.5 Metabolic Diseases    
    7.6 Musculoskeletal Disorders    
    7.7 CNS Diseases    
    7.8 CVS Diseases    
    7.9 Wounds and Injuries     
    7.10 Other Diseases    
       
8 Regulatory Landscape (Slide No. - 134)      
    8.1 North America    
    8.2 Asia-Pacific    
    8.3 Europe    
    8.4 ROW (Rest of The World)    
       
9 By Geography (Slide No. - 148)      
    9.1 Introduction    
    9.2 North America    
    9.3 Europe    
    9.4 Asia-Pacific    
    9.5 ROW (Rest of The World)    
       
10  Competitive Landscape (Slide No. - 173)     
    10.1 Overview    
    10.2 Competitive Situation & Trends    
       
11 Company Profiles (Slide No. - 183)      
    11.1 Aastrom Biosciences Inc.     
    11.2 Advanced Cell Technologies, Inc.    
    11.3 Athersys Inc.     
    11.4 Celgene Corporation     
    11.5 Cellular Dynamics International    
    11.6 Cytori Therapeutics, Inc.     
    11.7 Fibrocell Science, Inc.    
    11.8 Gamida Cell Ltd.    
    11.9 Mesoblast Ltd.    
    11.10 Pluristem Therapeutics Inc.    
    11.11 Stemcells Inc.     
       
       
List of Tables (58 Tables)      

Table 1 Global Market, By Mode of Therapy, 2013–2020 ($Million)      
Table 2 Investor Network for Stem Cell Therapy Market: Private and Government Investments      
Table 3 Investor Network Market: Private and Government Investments      
Table 4 Investor Network Market: Government Investments      
Table 5 Global Market, By Mode of Therapy, 2013–2020 ($Million)      
Table 6 Global Market, By Geography, 2013–2020 ($Million)      
Table 7 Global Allogeneic Stem Cell Therapy Market, By Application, 2013–2020 ($Million)      
Table 8 Global Allogeneic Stem Cell Therapy Market, By Geography, 2013–2020 ($Million)      
Table 9 Allogeneic Stem Cell Therapy Market for Eye Diseases, By Geography, 2013–2020 ($Million)      
Table 10 Allogeneic Market for GIT Diseases, By Geography, 2013–2020 ($Million)      
Table 11 Allogeneic Market for Immune System Diseases, By Geography, 2013–2020 ($Million)      
Table 12 Allogeneic Market for Metabolic Diseases, By Geography, 2013–2020 ($Million)      
Table 13 Allogeneic Market for Musculoskeletal Disorders , By Geography, 2013–2020 ($Million)      
Table 14 Allogeneic Market for CNS Diseases, By Geography, 2013–2020 ($Million)      
Table 15 Allogeneic Market for CVS Diseases, By Geography, 2013–2020 ($Million)      
Table 16 Allogeneic Market for Wounds & Injuries, By Geography, 2013–2020 ($Million)      
Table 17 Allogeneic Market for Other Diseases, By Geography, 2013–2020 ($Million)      
Table 18 Global Autologous Stem Cell Therapy Market, By Application, 2013–2020 ($Million)      
Table 19 Global Autologous Market, By Geography, 2013–2020 ($Million)      
Table 20 Autologous Market for GIT Diseases, By Geography, 2013–2020 ($Million)      
Table 21 Autologous Market for CNS Diseases, By Geography, 2013–2020 ($Million)      
Table 22 Autologous Market for Musculoskeletal Disorders , By Geography, 2013–2020 ($Million)      
Table 23 Autologous Market for Wounds & Injuries, By Geography, 2013–2020 ($Million)      
Table 24 Autologous Market for CVS Diseases, By Geography, 2013–2020 ($Million)      
Table 25 Autologous Market for Other Diseases, By Geography, 2013–2020 ($Million)      
Table 26 Global Market, By Application, 2013–2020 ($Million)      
Table 27 Market for Eye Diseases, By Geography, 2013–2020 ($Million)      
Table 28 Market for GIT Diseases, By Geography, 2013–2020 ($Million)      
Table 29 Market for Immune System Diseases, By Geography, 2013–2020 ($Million)      
Table 30 Market for Metabolic Diseases, By Geography, 2013–2020 ($Million)      
Table 31 Market for Musculoskeletal Disorders, By Geography, 2013–2020 ($Million)      
Table 32 Market for CNS Diseases, By Geography, 2013–2020 ($Million)      
Table 33 Market for CVS Diseases, By Geography, 2013–2020 ($Million)      
Table 34 Market for Wounds & Injuries, By Geography, 2013–2020 ($Million)      
Table 35 Market for Other Diseases, By Geography, 2013–2020 ($Million)      
Table 36 Regulatory Landscape In U.S. – Fda Guidance Documents       
Table 37 North America: Market, By Mode of Therapy, 2013–2020 ($Million)      
Table 38 North America: Market, By Therapeutic Application, 2013–2020 ($Million)      
Table 39 North America: Market, By Allogeneic Therapeutic Application, 2013–2020 ($Million)      
Table 40 North America: Market, By Autologous Therapeutic Application, 2013–2020 ($Million)      
Table 41 Europe: Market, By Mode of Therapy, 2013–2020 ($Million)      
Table 42 Europe: Market, By Therapeutic Application, 2013–2020 ($Million)      
Table 43 Europe: Market, By Allogeneic Therapeutic Application, 2013–2020 ($Million)      
Table 44 Europe: Market, By Autologous Therapeutic Application, 2013–2020 ($Million)      
Table 45 Asia-Pacific: Market, By Mode of Therapy, 2013–2020 ($Million)      
Table 46 Asia-Pacific: Market, By Therapeutic Application, 2013–2020 ($Million)      
Table 47 Asia-Pacific: Market, By Allogeneic Therapeutic Application, 2013–2020 ($Million)      
Table 48 Asia-Pacific: Market, By Autologous Therapeutic Application, 2013–2020 ($Million)      
Table 49 ROW: Market, By Mode of Therapy, 2013–2020 ($Million)      
Table 50 ROW: Market, By Therapeutic Application, 2013–2020 ($Million)      
Table 51 ROW: Market, By Allogeneic Therapeutic Application, 2013–2020 ($Million)      
Table 52 ROW: Market, By Autologous Therapeutic Application, 2013–2020 ($Million)      
Table 53 Product Approvals      
Table 54 Partnerships, Collaborations, & Agreements      
Table 55 Partnerships, Collaborations, & Agreements      
Table 56 Acquisitions      
Table 57 Patents       
Table 58 Other Developments       

List of Figures (32)     

Figure 1 Market Segmentation, By Application      
Figure 2 Market Segmentation, By Mode of Therapy      
Figure 3 Pipeline Analysis, Based on Regulatory Authority, 2011-2013      
Figure 4 Pipeline Analysis, Based on Country, 2011-2013      
Figure 5 Pipeline Analysis, Based on Phase Under Clinical Trial, 2011-2013      
Figure 6 Pipeline Analysis, Based on No. of Patients Enrolled, 2011-2013      
Figure 7 Pipeline Analysis, Overall Therapy Based on Source of Cell Extraction, 2011-2013      
Figure 8 Pipeline Analysis, Allogeinic Therapy Based on Clinical Trial Phases, 2011-2013      
Figure 9 Pipeline Analysis, Autologous Therapy Based on Clinical Trial Phases, 2011-2013      
Figure 10 Pipeline Analysis, By Application, 2011-2013      
Figure 11 Pipeline Analysis, Allogeinic Therapy Based on Therapeutic Areas, 2011-2013      
Figure 12 Pipeline Analysis, Autologous Therapy Based on Therapeutic Areas, 2011-2013      
Figure 13 Overall Market: Based on Cell Lines Used, 2011-2013      
Figure 14 Allogeneic Stem Cell Therapy Market: Based on Cell Lines Used, 2011-2013      
Figure 15 Autologous Stem Cell Therapy Market: Based on Cell Lines Used, 2011-2013      
Figure 16 Pipeline Analysis of Stem Cell Therapy Market: Based on Major Companies, 2011-2013      
Figure 17 Investor Network for Stem Cell Therapy Market: Nih (U.S.) Funding      
Figure 18 Market Segmentation, By Mode of Therapy      
Figure 19 Comparison Between Allogeneic & Autologous Stem Cell Therapy Market      
Figure 20 Estimated Cost Involved in The Manufacturing of Stem Cell Therapy Product      
Figure 21 Allogeneic Stem Cell Therapy Market Segmentation, By Mode of Therapy      
Figure 22 Autologous Stem Cell Therapy Market Segmentation, By Mode of Therapy      
Figure 23 Market Segmentation, By Mode of Therapy      
Figure 24 Stem Cell Therapy Process      
Figure 25 Stem Cell Research Policies and Legislations      
Figure 26 Geographic Distribution of CTG-Registered Stem Cell Therapy-Based Clinical Trials, 2000-2012      
Figure 27 Evolution of Stem Cell Research, North America      
Figure 28 Evolution of Stem Cell Research, Europe       
Figure 29 Evolution of Stem Cell Research, Asia-Pacific      
Figure 30 Key Growth Strategies, 2010-2014      
Figure 31 Share of Key Companies in Patents Category, 2010-2014      
Figure 32 Share of Key Companies in Product Approvals Category, 2010-2014

The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and is also expected to grow at a higher CAGR than autologous therapies from 2015 to 2020. Based on the therapeutic applications, the global market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others.

The global stem cell therapy market is expected to reach $330 million by 2020, at a CAGR of 39.5% from 2015 to 2020.

A number of factors such as increasing funding from government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the global market. Furthermore, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cells therapy are other factors that are propelling the growth of the market. In addition, increasing stem cell researches in developing markets, emergence of the induced pluripotent stem (iPS) cells as an alternative to ESCs, and the evolution of novel stem cell therapies unfolds new avenues for the growth of this market.

However, a few pivotal factors such as lack of required infrastructure (especially in emerging nations), ethical issues related to embryonic stem cell, and difficulties related with the preservation of stem cell are hindering the growth of this market. Moreover, dearth of reimbursements and high costs incurred in stem cell processing are the foremost challenges faced by the industry players.

The global stem cell market in 2015is expected to be dominated by North America, followed by Asia-Pacific and Europe. However, Asia-Pacific market is expected to surpass North America by 2020, owing to the high number of ongoing research activities. Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered in Japan, South Korea, China, and India. A number of factors such as the increasing regulatory support through favourable government policies, strong product pipelines, increasing licensing activities, and growing focus of both international and domestic players on the Asia-Pacific stem cell therapy market pose as the key drivers to the growth of market.

The stem cell therapy market includes large number of players that are involved in the development of stem cell therapy products for the treatment of various diseases. Leading market players in the market are focusing on partnerships/collaborations/agreements to commercialize their stem cell therapy. Mesoblast Ltd. (Australia), Aastrom Biosciences Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are the key players involved in the development of stem cell therapies.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Stem Cell Markets on KnowledgeStore
Request Demo Now